EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Dynamics-Guided Repositioning of FDA-Approved Drugs for PD-L1 Inhibition with In Vitro Anticancer Potential

Dejun Jiang iD, Myoung-Schook Yoou, Sungjoon Cho, Youngjin Choi iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26104497 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Dejun Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental Engineering, Hoseo University, Asan 31499, Republic of Korea. Hauptthemen laut MEDLINE: B7-H1 Antigen, Molecular Dynamics Simulation, Drug Repositioning, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF), Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Programmed death-ligand 1 (PD-L1) is a crucial immune checkpoint protein that tumors often exploit to evade immune surveillance. This study systematically screened a library of 1031 FDA-approved drugs using a high-throughput molecular dynamics approach to identify potential inhibitors targeting PD-L1. From this screening, five promising compounds—vorapaxar, delafloxacin, tenofovir disoproxil, pivmecillinam, and fursultiamine—showed significant binding affinities to PD-L1 and demonstrated cytotoxic activity against A549 lung tumor cells. These candidates were further evaluated through extended molecular dynamics simulations lasting up to 150 ns to assess their structural stability, residue fluctuations, and binding free energy. Among the identified compounds, pivmecillinam demonstrated the most favorable results, exhibiting stable binding interactions and a binding free energy of −18.01 kcal/mol, comparable to that of the known PD-L1 inhibitor BMS-1. These findings suggest that pivmecillinam has promising immunomodulatory potential and could serve as a candidate for further development in cancer immunotherapy. Overall, this study underscores the value of integrating high-throughput MD and experimental approaches for drug repositioning to identify novel therapeutic agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenMolecular Dynamics SimulationDrug RepositioningAntineoplastic AgentsImmune Checkpoint InhibitorsHumansA549 CellsUnited States Food and Drug AdministrationMolecular Docking SimulationProtein BindingDrug Approval

Stichwörter der Autor:innen

PD-L1cancerdrug repositioningmolecular dynamics simulationvirtual screening

Substanzen

B7-H1 AntigenCD274 protein, humanAntineoplastic AgentsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Environmental Engineering, Hoseo University, Asan 31499, Republic of Korea.
  • Eulji Medi-Bio Research Institute, Eulji University, Daejeon 34824, Republic of Korea.
  • Department of Bio-Applied Toxicology, Hoseo University, Asan 31499, Republic of Korea.
  • Department of Food Science & Technology, Hoseo University, Asan 31499, Republic of Korea.

ORCID-Profile: Dejun Jiang, Youngjin Choi

Förderung

  • National Research Foundation of Korea (NRF)
  • Ministry of Education

Zitieren

APA

Jiang, D., Yoou, M. S., Cho, S., & Choi, Y. (2025). Molecular Dynamics-Guided Repositioning of FDA-Approved Drugs for PD-L1 Inhibition with In Vitro Anticancer Potential. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104497

Vancouver

Jiang D, Yoou MS, Cho S, Choi Y. Molecular Dynamics-Guided Repositioning of FDA-Approved Drugs for PD-L1 Inhibition with In Vitro Anticancer Potential. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104497

BibTeX
@article{Jiang2025,
  author = {Jiang, Dejun and Yoou, Myoung-Schook and Cho, Sungjoon and Choi, Youngjin},
  title = {Molecular Dynamics-Guided Repositioning of FDA-Approved Drugs for PD-L1 Inhibition with In Vitro Anticancer Potential},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26104497}
}
Kostenlos starten →